MiMedx filed a lawsuit against Surgenex for alleged patent infringement of placental allograft products, seeking damages and injunction.
Quiver AI Summary
MiMedx Group, Inc. has initiated a lawsuit against Surgenex, LLC in the U.S. District Court for the District of Arizona, claiming that Surgenex's placental allograft products infringe on MiMedx's patents. The company seeks both a permanent injunction and monetary damages. This legal action marks the second lawsuit MiMedx has filed against Surgenex in 2024, following accusations related to corporate raiding and unfair competitive practices. MiMedx CEO Joseph H. Capper emphasized the company's robust patent portfolio and its commitment to protecting its intellectual property in the face of competitors infringing on their innovations. MiMedx is focused on providing wound care solutions and aims to maintain its leadership in the market through continuous innovation.
Potential Positives
- MiMedx Group, Inc. is actively protecting its intellectual property by filing a lawsuit against Surgenex, which may strengthen its market position and deter future infringements.
- The lawsuit emphasizes MiMedx's extensive patent portfolio, showcasing the company's innovation and leadership in the development of placental allograft products.
- This legal action indicates MiMedx's commitment to maintaining its competitive edge amidst a rapidly evolving market for skin substitutes.
- The company’s proactive stance in litigation may enhance its reputation as a serious player in the wound care and healing solutions industry.
Potential Negatives
- The announcement of the second lawsuit indicates ongoing legal battles for MiMedx Group, which may lead to increased scrutiny and concerns about the company's business practices and competitive tactics.
- The mention of a "corporate raiding scheme" in ongoing litigation raises potential ethical concerns regarding the company's operations and interactions with competitors.
- The focus on patent infringement suggests that MiMedx may be struggling to keep up with competitors in the rapidly evolving market for placental allografts, which could impact its market position and reputation as an industry leader.
FAQ
What is the recent lawsuit filed by MiMedx about?
MiMedx filed a lawsuit against Surgenex for allegedly infringing on its patents related to placental allograft products.
How many lawsuits has MiMedx filed against Surgenex?
This is the second lawsuit MiMedx has filed against Surgenex this year, following earlier litigation regarding corporate raiding.
What does MiMedx seek from the lawsuit against Surgenex?
MiMedx seeks permanent injunctive relief and monetary damages from Surgenex for the patent infringement.
Who is the CEO of MiMedx?
Joseph H. Capper is the Chief Executive Officer of MiMedx Group, Inc.
What is MiMedx's focus in the healthcare industry?
MiMedx specializes in providing healing solutions for chronic wounds, burns, and surgical applications through innovative products.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$MDXG Hedge Fund Activity
We have seen 79 institutional investors add shares of $MDXG stock to their portfolio, and 114 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- TRIGRAN INVESTMENTS, INC. added 3,211,623 shares (+71.7%) to their portfolio in Q3 2024
- ARROWSTREET CAPITAL, LIMITED PARTNERSHIP removed 841,096 shares (-93.1%) from their portfolio in Q3 2024
- HARBOR CAPITAL ADVISORS, INC. added 770,744 shares (+299.9%) to their portfolio in Q3 2024
- PUNCH & ASSOCIATES INVESTMENT MANAGEMENT, INC. added 598,430 shares (+52.1%) to their portfolio in Q3 2024
- PARADIGM CAPITAL MANAGEMENT INC/NY added 496,900 shares (+11.9%) to their portfolio in Q3 2024
- SEGALL BRYANT & HAMILL, LLC removed 455,384 shares (-100.0%) from their portfolio in Q3 2024
- NORGES BANK removed 418,600 shares (-85.6%) from their portfolio in Q2 2024
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
MARIETTA, Ga., Dec. 17, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it has filed a lawsuit against Surgenex, LLC in the United States District Court for the District of Arizona. The complaint asserts that several of Surgenex’s placental allograft products infringe the Company’s patents and seeks permanent injunctive relief and monetary damages. This matter represents the second lawsuit by MIMEDX against Surgenex, following ongoing litigation filed earlier this year alleging a corporate raiding scheme on the Company’s commercial organization and unfair competitive practices.
Joseph H. Capper, MIMEDX Chief Executive Officer, commented, “As an industry pioneer and long-standing developer of placental allografts, MIMEDX has amassed an extensive portfolio of more than 70 patents, including some of the earliest IP in the category. It has recently come to our attention that this competitor, and possibly others, has infringed on our proprietary intellectual property. Given the rapid proliferation of skin substitutes entering the market over the past few years, we will likely uncover several more infringing products as we expand our investigation and analysis. As we do, we will aggressively exercise our right to protect these important assets.”
About MIMEDX
MIMEDX is a pioneer and leader focused on helping humans heal. With more than a decade of helping clinicians manage chronic and other hard-to-heal wounds, MIMEDX is dedicated to providing a leading portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. The Company’s vision is to be the leading global provider of healing solutions through relentless innovation to restore quality of life. For additional information, please visit www.mimedx.com .
Contact:
Matt Notarianni
Investor Relations
470-304-7291
mnotarianni@mimedx.com